摘要
Background: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy. @@@ Methods: A total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD. @@@ Findings: Overall, 10 (14.49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0.931 (95% confidence interval, 0.844-1.000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (p < 0.001). However, there was no significant difference in OS between PD (progressive disease) patients with and without HPD (p = 0.05). @@@ Interpretation: We identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy.
学科与关键词
- Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitorsXiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Annals of Palliative Medicine, 2021, 10(11): 11244-+.被引 7
- Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-CancerChen, Shiyun; Gou, Miaomiao; Yan, Huan; Fan, Mengjiao; Pan, Yuting; Fan, Runjia; Qian, Niansong*; Dai, Guanghai*DISEASE MARKERS, 2021, 2021: 6639366.被引 13
- Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysisLi, Yangyang; Liu, Wendao; Chen, Junwei; Chen, Yongxin; Guo, Jiandong; Pang, Huajin; Zhang, Wentao; An, Chao*; Li, Chengzhi*Cancer Medicine, 2024, 13(1).
